期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (8)
In view of the increasing number of malignant tumors worldwide and their high mortality, efforts are being made to find effective biomarkers for early......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (7)
The aim of this study was to investigate the prognostic significance of BRAF(V600E) in cell-free (cf) DNA(cfBRAF(V600E)) and lesion tissues (ltBRAF(V6......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (9)
The objective of this study was to evaluate the real-world application, efficacy, and safety data of olaparib for maintenance therapy and active treat......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (7)
Glioblastoma (GBM), as the immunologically cold tumor, respond poorly to programmed cell death 1 (PD-1) immune checkpoint inhibitors because of insuff......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (6)
Mutations in the neurofibromatosis type 2 (NF2) gene that limit or abrogate expression of functional Merlin are common in malignant mesothelioma. Merl......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (8)
Targeted, catalytic degradation of oncoproteins using heterobi-functional small molecules is an attractive modality, particularly for hematologic mali......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (6)
Breast cancer bone metastases are common and incurable. Tumoral integrin beta 3 (beta 3) expression is induced through interaction with the bone micro......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (9)
Solid tumors start as a local disease, but some are capable of metastasizing to the lymph nodes and distant organs. The hypoxic microenvironment, whic......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (4)
Gain-of-function point mutations in the receptor tyrosine kinase RET, a driver oncogene in medullary thyroid carcinoma (MTC), prevent apoptosis throug......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (9)
We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi; olaparib) and CDK4/6 inhibition (CDK4/6i; palbociclib or abemaciclib)......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (6)
Calicheamicin antibody-drug conjugates (ADCs) are effective therapeutics for leukemias with two recently approved in the United States: Mylotarg (gemt......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (2)
Glioblastoma multiforme (GBM; grade IV glioma) is the most malignant type of primary brain tumor and is characterized by rapid proliferation and invas......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (1)
Staphylococcal nuclease domain-containing protein 1 (SND1) is a multifunctional oncoprotein overexpressed in breast cancer. Binding of metadherin (MTD......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (1)
Pancreatic ductal adenocarcinoma (PDAC) has a prominent fibrotic stroma, which is a result of interactions between tumor, immune and pancreatic stella......
期刊： MOLECULAR CANCER THERAPEUTICS, 2021; 20 (1)
The PI3K/AKT/mTOR pathway is often activated in lymphoma through alterations in PI3K, PTEN, and B-cell receptor signaling, leading to dysregulation of......
